Evogene Annual Meeting Adjourned Due to Lack of Quorum
Ticker: EVGN · Form: 6-K · Filed: Aug 11, 2025 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, adjournment, quorum
TL;DR
Evogene's shareholder meeting postponed to Aug 18 due to no-shows. Big decisions on hold.
AI Summary
Evogene Ltd. held its Annual General Meeting of Shareholders on August 11, 2025, but it was adjourned for one week due to a lack of quorum. The meeting will now reconvene on August 18, 2025, at 3:00 PM at the same location.
Why It Matters
The adjournment of the annual meeting means key shareholder decisions may be delayed, potentially impacting the company's strategic direction and operations.
Risk Assessment
Risk Level: low — The adjournment is a procedural matter and does not inherently indicate financial distress or operational failure.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- August 11, 2025 (date) — Original Annual General Meeting date
- August 18, 2025 (date) — Reconvened Annual General Meeting date
FAQ
Why was the Annual General Meeting of Shareholders adjourned?
The meeting was adjourned due to a lack of quorum.
When will the Evogene Annual General Meeting reconvene?
The meeting will reconvene on Monday, August 18, 2025.
What time is the reconvened meeting?
The reconvened meeting is scheduled for 3:00 PM.
Where will the reconvened meeting be held?
The meeting will be held at the same place as the original meeting.
What is the company's principal executive office address?
The company's principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-08-11 16:01:42
Filing Documents
- zk2533601.htm (6-K) — 9KB
- 0001178913-25-002750.txt ( ) — 10KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On August 11, 2025, Evogene Ltd. (the " Company ") convened its Annual General Meeting of Shareholders (the " Annual Meeting "), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Annual General Meeting will be reconvened on Monday, August 18, 2025 at 3:00 p.m. (Israel time), at the executive offices of the Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. The content of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565 ) and on Form S-8 (File Nos. 333-193788 , 333-201443 , 333-203856 , 333-259215 and 333-286197 ) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 11, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer